A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
A candidate hepatitis E vaccine is composed of amino acids (aa) 112-607 of the 660-aa protein encoded by open reading frame 2 (ORF2) of hepatitis E virus (HEV). We have studied the antibody response to vaccine-associated epitopes and to epitopes excluded from the vaccine to determine if important epitopes were omitted from the vaccine and if antibody responses to these regions could be used to differentiate between infection and vaccination. ELISAs were developed based on genotype 1 ORF2 peptides, containing aa 112-607 (vaccine), 458-607 (minimum neutralization site), 1-111 (N-terminus) and 607-660 (C-terminus), as well as on ORF3 peptides, containing aa 1-123 (complete) and 91-123 (C-terminus). All naive macaques infected with HEV genotype 1, 2, 3 or 4 produced antibodies to all ORF2 peptides. Anti-ORF3 was detected in both monkeys infected with genotype 1 virus and in one of two infected with genotype 2 virus. These antibody responses were considerably weaker than those directed against the neutralization site. In contrast, vaccinated animals that were challenged with HEV had a diminished or absent immune response to the peptides not included in the vaccine. Thus, only minor epitopes were excluded from the vaccine; they had limited utility for distinguishing between vaccination and infection.
Zhou
Yi-Hua
YH
Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive MSC-8009, Bethesda, MD 20892, USA. vzhou@niaid.nih.gov
Purcell
Robert H
RH
Emerson
Suzanne U
SU
D000818:Animals; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis / Q000096:biosynthesis*; D016751:Hepatitis E / Q000517:prevention & control*; D016752:Hepatitis E virus / Q000276:immunology*; D008253:Macaca mulatta; D010446:Peptide Fragments / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D036022:Capsid Proteins; D017931:DNA Primers; D006023:Glycoproteins; D006508:Hepatitis Antibodies; D010446:Peptide Fragments; D014761:Viral Hepatitis Vaccines